<?xml version='1.0' encoding='utf-8'?>
<document id="16049129"><sentence text="In vitro metabolism of the calmodulin antagonist DY-9760e (3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride 3.5 hydrate) by human liver microsomes: involvement of cytochromes p450 in atypical kinetics and potential drug interactions."><entity charOffset="49-190" id="DDI-PubMed.16049129.s1.e0" text="DY-9760e (3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride 3.5 hydrate" /></sentence><sentence text="Human cytochrome P450 (P450) isozyme(s) responsible for metabolism of the calmodulin antagonist 3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride 3"><entity charOffset="96-215" id="DDI-PubMed.16049129.s2.e0" text="3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride" /></sentence><sentence text="5 hydrate (DY-9760e) and kinetic profiles for formation of its six primary metabolites [M3, M5, M6, M7, M8, and DY-9836 (3-[2-[4-(3-chloro-2-methylphenyl)piperazinyl]ethyl]-5,6-dimethoxyindazole)] were identified using human liver microsomes and recombinant P450 enzymes"><entity charOffset="0-9" id="DDI-PubMed.16049129.s3.e0" text="5 hydrate" /><entity charOffset="11-19" id="DDI-PubMed.16049129.s3.e1" text="DY-9760e" /><pair ddi="false" e1="DDI-PubMed.16049129.s3.e0" e2="DDI-PubMed.16049129.s3.e0" /><pair ddi="false" e1="DDI-PubMed.16049129.s3.e0" e2="DDI-PubMed.16049129.s3.e1" /></sentence><sentence text=" In vitro experiments, including an immunoinhibition study, correlation analysis, and reactions with recombinant P450 enzymes, revealed that CYP3A4 is the primary P450 isozyme responsible for the formation of the DY-9760e metabolites, except for M5, which is metabolized by CYP2C9" /><sentence text=" Additionally, at clinically relevant concentrations, CYP2C8 and 2C19 make some contribution to the formation of M3 and M5, respectively" /><sentence text=" The formation rates of DY-9760e metabolites except for M8 by human liver microsomes are not consistent with a Michaelis-Menten kinetics model, but are better described by a substrate inhibition model" /><sentence text=" In contrast, the enzyme kinetics for all metabolites formed by recombinant CYP3A4 can be described by an autoactivation model or a mixed model of autoactivation and biphasic kinetics" /><sentence text=" Inhibition of human P450 enzymes by DY-9760e in human liver microsomes was also investigated" /><sentence text=" DY-9760e is a very potent competitive inhibitor of CYP2C8, 2C9 and 2D6 (Ki 0" /><sentence text="25-1" /><sentence text="7 microM), a mixed competitive and noncompetitive inhibitor of CYP2C19 (Ki 2" /><sentence text="4 microM) and a moderate inhibitor of CYP1A2 and 3A4 (Ki 11" /><sentence text="4-20" /><sentence text="1 microM), suggesting a high possibility for human drug-drug interaction" /><sentence text="" /></document>